What is BioFluidica?
BioFluidica is a privately held biotechnology company that has developed a groundbreaking microfluidic platform capable of capturing and isolating disease biomarkers, such as Circulating Tumor Cells (CTCs), directly from a simple blood test. This technology has been clinically validated and offers unparalleled sensitivity in scanning whole blood for the earliest signs of disease, fulfilling the promise of a true liquid biopsy. By enabling the detection of the rarest biomarkers, BioFluidica is poised to revolutionize disease detection and management, bringing advanced diagnostic capabilities to millions.
How much funding has BioFluidica raised?
BioFluidica has raised a total of $12.5M across 5 funding rounds:
Series A
$2M
Private Equity
$4.1M
Debt
$150K
Debt
$208K
Series B
$6M
Series A (2016): $2M, investors not publicly disclosed
Private Equity (2017): $4.1M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Debt (2021): $208K featuring PPP
Series B (2022): $6M, investors not publicly disclosed
What's next for BioFluidica?
With the recent Series B financing, BioFluidica is well-positioned to scale its operations and further develop its proprietary microfluidic technology. This substantial backing suggests a strategic focus on expanding clinical validation, enhancing manufacturing capabilities, and potentially entering new therapeutic areas or diagnostic markets. The company's ability to secure major enterprise-level funding indicates strong investor belief in its potential to disrupt the diagnostics industry and improve patient outcomes through advanced liquid biopsy solutions.
See full BioFluidica company page
